# Pharmacophore modeling: advances and pitfalls

## TL;DR

Pharmacophore modeling has become a key tool in drug discovery, with recent advances improving accuracy but still facing challenges like conformational bias and computational costs.

## Contribution

The paper highlights novel multi-pharmacophore strategies and dynophores, as well as AI integration to improve pharmacophore modeling.

## Key findings

- Multi-pharmacophore strategies and dynophores better capture ligand diversity and dynamic interactions.
- AI and machine learning enhance pharmacophore feature extraction and virtual screening accuracy.
- Current methods still face limitations due to conformational bias and computational costs.

## Abstract

Pharmacophore modeling has evolved from a static conceptual framework into a central computational tool in modern drug discovery. Recent advances include multi-pharmacophore strategies that better capture ligand diversity and target flexibility, as well as dynamic pharmacophore models (“dynophores”) derived from molecular dynamics simulations that reflect time-dependent interaction patterns. The integration of artificial intelligence and machine learning has further improved feature extraction, virtual screening accuracy, and predictive performance across discovery pipelines. Despite these advances, pharmacophore modeling remains constrained by conformational bias, limited binding-mode representation, and computational cost. Case studies involving efflux pumps, topoisomerase IIα, and LEDGF/p75–integrase inhibitors illustrate both the strengths and limitations of current methods. Collectively, these developments underscore the value of hybrid approaches to enhance pharmacophore reliability and real-world utility.